BioMarin, following sluggish sales, to offload hemophilia gene therapy
Oct 27, 2025 · BioMarin Pharmaceutical is giving up on the hemophilia gene therapy Roctavian, announcing on Monday plans to offload a first-of-its-kind medicine once expected to become a future …
BioMarin keeps but scales down Roctavian gene therapy ops
2 days ago · BioMarin Pharma has decided not to divest its haemophilia A gene therapy Roctavian, which has struggled to build much traction in the market, but is reining back its ambitions for the …
BioMarin Announces Updated Strategy for ROCTAVIAN® to Focus on …
Aug 5, 2024 · The company has already begun to operationalize the reduction of ROCTAVIAN expenses this year to achieve $60 million in expenses beginning in full-year 2025. As a result of …
Biomarin limits Roctavian development to US, Germany, Italy
Aug 9, 2024 · In an effort to cut costs and boost profitability, Biomarin Pharmaceutical is limiting commercial development of hemophilia A gene therapy Roctavian (valoctocogene roxaparvovec …
ROCTAVIAN® | Gene Therapy Treatment for Hemophilia
ROCTAVIAN® (valoctocogene roxaparvovec-rvox) is a one-time gene therapy treatment for eligible adults with severe hemophilia A. Get safety information and learn how it works.
BioMarin’s Presence in Rare Enzyme Disorders Grows With $4.8B …
Dec 19, 2025 · Rare disease drug developer BioMarin Pharmaceutical is buying its way to revenue growth with a $4.8 billion deal for Amicus Therapeutics, a company whose two commercialized …
Valoctocogene roxaparvovec - Wikipedia
Valoctocogene roxaparvovec, sold under the brand name Roctavian, is a gene therapy used for the treatment of hemophilia A. [1][3] It was developed by BioMarin Pharmaceutical. [4][5][6] …
BioMarin Restructures ROCTAVIAN Program to Improve Profitability
Aug 7, 2024 · BioMarin Pharmaceutical Inc. is updating its ROCTAVIAN business to focus commercial operations on three markets—the United States, Germany and Italy— where the medicine is …
BioMarin narrows Roctavian strategy to US, Germany and Italy
Aug 6, 2024 · BioMarin Pharmaceutical announced a shift in its strategy for its struggling haemophilia A gene therapy Roctavian (valoctocogene roxaparvovec-rvox), saying it will concentrate its efforts on …
BioMarin Announces Updated Strategy for ROCTAVIAN® to Focus on …
Aug 5, 2024 · The company develops and commercializes targeted therapies that address the root cause of genetic conditions.